◀ Back to CDK2

CDK2 — MAPK1

Pathways - manually collected, often from reviews:

• NCI Pathway Database IL2-mediated signaling events: Erk1-2-active (MAPK3/MAPK1) → CDK2 (CDK2) (translocation, activates) Blanchard et al., Oncogene 2000
  Evidence: mutant phenotype

Text-mined interactions from Literome

Yang et al., J Am Coll Cardiol 2000 : Cerivastatin reduced the 3H-thymidine incorporation ( 164 +/- 11 %, p < 0.01 ), inhibited Cdk2 activation and Rb phosphorylation, but did not prevent p27Kip1 down-regulation, nor p42mapk and p70S6K activation
Liu et al., Di Yi Jun Yi Da Xue Xue Bao 2002 (Cardiomyopathy, Hypertrophic...) : [ Regulation of cyclin dependent kinase inhibitors by mitogen activated protein kinase in angiotensin II-stimulated vascular smooth muscle cell hypertrophy ] ... To investigate the role of mitogen activated protein kinase ( MAPK ) in the regulation of cyclin dependent kinase inhibitors ( CDKI ) in the process of vascular smooth muscle cell ( VSMC ) hypertrophy induced by angiotensin II stimulation
Corrèze et al., Eur J Endocrinol 2005 : These results indicate that p38 MAPK activity is involved in the regulation of cell cycle progression in FRTL-5 thyroid cells, at least in part by increasing nuclear Cdk2 activity
Lee et al., J Cell Biochem 2006 : In addition, PD 98059 ( a MEK inhibitor ), SB 203580 ( a p38 MAPK inhibitor ), and SP 600125 ( a JNK inhibitor ) blocked the EGF induced stimulation of [ 3H ] -thymidine incorporation and CDK-2/4 expression